Without the rise of biopharmaceuticals, would separation science and mass spectrometry be where they are today?

How we can best provide state-of-the-art proteomics technology to the biomedical community.

How we might reduce environmental impact without reducing capability – and why we should try

Sitting Down With… Steven Carr, Proteomics Platform Director at the Broad Institute of MIT and Harvard.

New sites devoted to post-publication peer review open up great opportunities for dialog; so long as we can all agree on a clear code of conduct.

How we go about the systematic study of the unique chemical fingerprints that specific cellular processes leave behind – and what we can learn from them.

The field of mass spectrometry imaging is enjoying constant – and exciting – progress.

In the face of increasing competition, standing out from the crowd requires more than good science. We must embrace self-marketing.

Common data file formats are readily available for mass spectrometry imaging (MSI) data. Now, the community must agree on an extensible cross-platform software solution that everyone can use.

Far too little respect for, and competency in, representative sampling is making a mockery of analytical error.